Synthesis, Structure–Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity

Author:

Akester Jessica N.1,Njaria Paul2,Nchinda Aloysius1,Le Manach Claire1,Myrick Alissa13,Singh Vinayak134ORCID,Lawrence Nina5,Njoroge Mathew5ORCID,Taylor Dale5,Moosa Atica6,Smith Anthony J.7,Brooks Elizabeth J.7,Lenaerts Anne J.7,Robertson Gregory T.7,Ioerger Thomas R.8,Mueller Rudolf1,Chibale Kelly1234ORCID

Affiliation:

1. Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa

2. Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa

3. Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa

4. South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa

5. H3D, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa

6. MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Rondebosch 7701, South Africa

7. Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 200 West Lake Street, Fort Collins, Colorado 80523, United States

8. Department of Computer Science, Texas A&M University, College Station, Texas 77843-3112, United States

Funder

Novartis Foundation

Bill and Melinda Gates Foundation

National Research Foundation

South African Medical Research Council

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Reference32 articles.

1. Treatment of Tuberculosis

2. Current Status and Research Strategies in Tuberculosis Drug Development

3. Quinoline Derivatives with Potential Activity Against Multidrug-resistant Tuberculosis

4. TB Alliance (2019) FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis, https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis (accessed 2020-02-24).

Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3